ชื่อล็อคอิน
รหัสผ่าน
ข่าวประจำวัน
ดูดวงออนไลน์
เกมส์
ท่องเที่ยว
รถยนต์
 
เนื้อเพลง
หาเพื่อน
สุขภาพ
ประกาศซื้อขาย
หางาน
ค้นหา


More People Treated With Once-weekly Semaglutide Achieved Reductions in Both Glucose and Weight vs. Comparator Treatments

หน้าแรก > ข่าวสุขภาพ-การแพทย์ > More People Treated With Once-weekly Semaglutide Achieved Reductions in Both Glucose and Weight vs. Comparator Treatments
ผู้โพส : Admin / วันที่โพส : 2017-09-12 23:15:01
คำค้นหา : Keyword: PRN


More People Treated With Once-weekly Semaglutide Achieved Reductions in Both Glucose and Weight vs. Comparator Treatments




          Poster # 820

          A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER). The analysis was presented today at the 53rd Annual Meeting of the European Association For The Study Of Diabetes.[1]

          "As a physician, helping patients with type 2 diabetes achieve glycaemic and weight loss targets can be challenging," said Dr Helena Rodbard, SUSTAIN 5 investigator and medical director at Endocrine and Metabolic Consultants, Rockville, Maryland. "The meaningful reductions demonstrated with semaglutide in both glucose and body weight are encouraging, as more treatment strategies are needed to help meet this challenge."

          Significantly more people treated with once-weekly semaglutide achieved the clinically meaningful composite endpoint of ≥1% HbA1c reduction and ≥5% weight loss with 0.5 mg (25-35%) and 1.0 mg (38-56%) semaglutide vs. all comparators (2-13%; p<0.0001) in SUSTAIN 1-5.[1]

          In addition, more people achieved the composite endpoint with once-weekly semaglutide 1.0 mg compared with semaglutide 0.5 mg (p<0.0001 for SUSTAIN 2, 4 and 5; p=0.17 for SUSTAIN 1).[1]

          In this post-hoc analysis, semaglutide was well tolerated, with a safety profile similar to that of other glucagon-like peptide-1 receptor agonists. The most common adverse event with semaglutide was nausea. In SUSTAIN 1-4, severe or blood glucose confirmed symptomatic hypoglycaemia events were fewer or similar with once-weekly semaglutide vs. comparators. In SUSTAIN 5, on a background of basal insulin, more events were observed with once-weekly semaglutide than with placebo.[1]

          About semaglutide

          Semaglutide is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake.[2]-[5] Once-weekly semaglutide is currently under review by seven regulatory agencies, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

          About the SUSTAIN clinical trial programme

          SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a clinical trial programme for semaglutide, administered once weekly, that comprises seven phase 3a global clinical trials and a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes.

          Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedInYouTube 

          Novo Nordisk A/S
          Corporate Affairs    
          Novo Alle
          2880 Bagsvaerd
          Denmark
          Telephone: +45-4444-8888
          Internet: http://www.novonordisk.com
          CVR no: 24 25 67 90

          References

          1. Rodbard H, Bellary S, Hramiak I, et al. Responder analysis of subjects achieving HbA1c ≥1% and weight loss ≥5% across SUSTAIN 1-5 clinical trials. Poster 802. 53rd Annual Meeting of the European Association For The Study Of Diabetes (EASD), Lisbon, Portugal; 11-15 September 2017.

          2. Korsatko A, Brunner M, Sach-Friedl S, et al. Effect of once-weekly semaglutide on the counter-regulatory response to hypoglycaemia in subjects with type 2 diabetes. Abstract 764. 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016.

          3. Kapitza C, Dahl K, Jaconsen B, et al. The effects of once-weekly semaglutide on beta-cell function in subjects with type 2 diabetes. Abstract 754. 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016.

          4. Blundell J, Finlayson G, Axelsen MB, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; ePub ahead of print. DOI: 10.1111/dom.12932.

          5. Saad H, Hjersted J, Axelsen MB, et al. Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity. Canadian Journal of Diabetes. 2016; 40:S34-S35.

          Further information
          Media:
          Katrine Sperling
          +45-4442-6718
          krsp@novonordisk.com

          Asa Josefsson
          +45-3079-7708
          aajf@novonordisk.com

          Investors:
          Peter Hugreffe Ankersen
          +45-3075-9085
          phak@novonordisk.com

          Hanna Ogren
          +45-3079-8519
          haoe@novonordisk.com

          Anders Mikkelsen
          +45-3079-4461
          armk@novonordisk.com

          Christina Jensen
          +45-3079-3009
          cnje@novonordisk.com

          Kasper Veje (US)
          +1-609-235-8567
          kpvj@novonordisk.com
 
          Source: Novo Nordisk

ขอขอบคุณ เนื้อหาจาก ThaiPr.net
 ข่าวล่าสุด
 
แสดงความคิดเห็น
ชื่อผู้โพส
รายละเอียด
อีโมติคอน

 ?ใส่รหัสลับ ใส่ให้ตรงกันครับ